Bexsero Booster Protection
GSK Seeks EMA Approval for Bexsero Booster to Extend Meningococcal B Protection in Older Youth
Anonymous
Key Points
1
IMD remains potentially life-threatening, with a fatality rate of 4-20% and survivors can face long-term sequelae.
2
Adolescents and young adults experience a second peak in IMD incidence, often linked to close-contact behaviours such as kissing, sharing drinks, and communal living.
3
GSK's finances show a dividend yield around 3.5%, with shares trading below key moving averages and ongoing considerations around leverage and free cash flow.
4
In 2024 in the EU/EEA, 56% of confirmed IMD cases were due to serogroup B in all age groups under 65, and up to 20% of IMD survivors have severe, life-altering sequelae.
The European Medicines Agency has accepted GSK's application to add a single-dose booster indication to the Bexsero meningococcal B vaccine, according to Nasdaq. The booster would cover people aged 10 and older who were first vaccinated as infants — potentially extending protection into adolescence and early adulthood.
Bexsero is already approved in 61 countries, with around 138 million doses distributed since its 2015 launch, TipRanks reported. If the EMA grants approval, it would be the first label update allowing a booster dose for this age group in Europe.
Why Teens Face a Second Wave of Meningitis B Risk
Meningococcal B disease — or MenB — is a fast-moving bacterial infection. It kills between 4% and 20% of those who catch it. Up to 20% of survivors face severe, long-term effects like limb loss or brain damage, according to MarketScreener.
Infants are vaccinated early, but protection can fade. Adolescents then hit a second peak of risk, driven by close-contact behaviors like kissing, sharing drinks, and communal living. In 2024, 56% of confirmed MenB cases in the EU and EEA occurred in people under 65, MarketScreener noted.
Phase 3b Data Backs the Single-Booster Approach
GSK's application is supported by Phase 3b trial data. The trial tested a single booster dose in people aged 10 to 20 who had received Bexsero as infants. Results showed the booster restored strong immune responses in that age group, according to Sharecast.
Full trial results are set to be presented at the International Pathogenic Neisseria Conference — known as the IPNC — in September, ADVFN reported. GSK has not yet disclosed specific antibody titer figures from the study ahead of that presentation.
What EMA Acceptance Actually Means for GSK
EMA acceptance means regulators have agreed to formally review the submission — it is not yet an approval. The agency will now assess the safety and efficacy data before deciding whether to update Bexsero's official prescribing label across Europe.
For GSK, a positive outcome would strengthen its vaccine portfolio in markets where infant MenB programs are already well established. Nasdaq noted the move also supports the company's broader growth strategy in vaccines, with investors watching the timeline for a final EMA decision.
Bexsero's Track Record Underpins the Booster Case
Bexsero has a decade-long safety record. Since launching in 2015, around 138 million doses have been given worldwide, TipRanks reported. That large base of real-world data gives regulators a strong foundation for evaluating any label expansion.
GSK shares currently trade below key moving averages, with a dividend yield of around 3.5%, according to market commentary. Analysts are tracking whether a successful EMA outcome could sharpen the company's earnings outlook heading into late 2025.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
11
Articles
3
Reach
14
Topics
A
AnonymousAuthor